PTIX
Protagenic Therapeutics, Inc. [PTIX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PTIX Stock Summary
Top 10 Correlated ETFs
PTIX
Top 10 Correlated Stocks
PTIX
In the News
PTIX Financial details
Company Rating
-
Market Cap
6.39M
Income
-5.01M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-0.95
Forward P/E
-
PEG
-0.25
P/S
-
P/B
0.9
P/C
-
P/FCF
-1.39
Quick Ratio
4.12
Current Ratio
4.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
38.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
18.75%
-
-
-
-
SMA20
-17.16%
SMA50
-55.99%
SMA100
-50.29%
Inst Own
-
Inst Trans
-
ROA
-73%
ROE
-69%
ROC
-0.96%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.68-2.32
52W High
-
52W Low
-
RSI
34.22
Rel Volume
10.8
Avg Volume
10.43K
Volume
112.62K
Perf Week
-8.29%
Perf Month
-32.79%
Perf Quarter
-54.64%
Perf Half Y
-52.97%
-
-
-
-
Beta
0.383
-
-
Volatility
0.03%, 0.23%
Prev Close
5.06%
Price
1.66
Change
3.75%
Company Profile
- Volume Average 10.43K
- Market Capitalization 6.39M
- Employee 1
- CEO Dr. Garo H. Armen Ph.D.
- Headquarters New York,NY,US
- IPO Date 2021-04-27
-
Website
https://www.protagenic.com 
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
